Dr Carolyn Luscombe, Head of Research and Development, has received an award at the HIV DART and Emerging Viruses 2018 in Miami, Florida for the presentation entitled
“BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial”.
The award is an acknowledgment of the importance of the outcomes from the Phase 2 trial data presented, as well as the robustness of the science underlying the Company’s programs.
DYOR
- Forums
- ASX - By Stock
- BIT won an award due to the presentation
Dr Carolyn Luscombe, Head of Research and Development, has...
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
3.4¢ |
Change
0.001(3.03%) |
Mkt cap ! $30.67M |
Open | High | Low | Value | Volume |
3.4¢ | 3.4¢ | 3.3¢ | $632 | 18.85K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 287617 | 3.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.5¢ | 37989 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 287617 | 0.033 |
3 | 215000 | 0.032 |
2 | 332500 | 0.031 |
8 | 540666 | 0.030 |
1 | 100000 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.035 | 10000 | 1 |
0.036 | 65500 | 1 |
0.037 | 537816 | 2 |
0.039 | 490546 | 3 |
0.040 | 113240 | 2 |
Last trade - 13.36pm 19/07/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |